{"title":"FUS/ strp5 /Wnt5在动脉粥样硬化中的表达及作用","authors":"Xiaogao Wang, Hui Wang, Ran Lu, Shiyuan Chen, Yong Gao, Chaowen Yu","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Atherosclerosis (AS) contributes significantly to the development of cardiovascular disease. Despite recent advances in medical treatment, the outcomes for patients with AS are still unsatisfactory. This study aims to enhance our understanding of AS and pave the way for the development of more effective therapeutic approaches to improve patient outcomes and ultimately reduce the burden of this devastating condition.</p><p><strong>Methods: </strong>An AS cell model was established using oxidized low-density lipoprotein (OX-LDL) administration to human vascular smooth muscle cells (HVSMCs), followed by injection with oe-NC, oe-FUS, oe-Sfrp5, or oe-FUS+ oe-Sfrp5. Western blot, Transwell assay, CCK8 assay, Oil Red O staining assay, and ELISA were used to elucidate the mechanisms of the FUS/Sfrp5/Wnt5 pathway in our model of AS.</p><p><strong>Results: </strong>In this study, both FUS and Sfrp5 inhibited Wnt5a expression. In addition, FUS inhibited lipid droplet formation and migration capacity of OX-LDL-induced HVSMCs, and FUS and Sfrp5 may have a synergistic effect in controlling Wnt5a in AS. These results highlight the potential therapeutic value of targeting the FUS and Sfrp5 pathway to control AS progression.</p><p><strong>Conclusion: </strong>The findings suggest that FUS and Sfrp5 may have a synergistic effect in controlling Wnt5a in AS.</p>","PeriodicalId":8228,"journal":{"name":"Annals of clinical and laboratory science","volume":"55 2","pages":"240-246"},"PeriodicalIF":1.1000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Expression and Effects of FUS/Sfrp5/Wnt5 in Atherosclerosis Development.\",\"authors\":\"Xiaogao Wang, Hui Wang, Ran Lu, Shiyuan Chen, Yong Gao, Chaowen Yu\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Atherosclerosis (AS) contributes significantly to the development of cardiovascular disease. Despite recent advances in medical treatment, the outcomes for patients with AS are still unsatisfactory. This study aims to enhance our understanding of AS and pave the way for the development of more effective therapeutic approaches to improve patient outcomes and ultimately reduce the burden of this devastating condition.</p><p><strong>Methods: </strong>An AS cell model was established using oxidized low-density lipoprotein (OX-LDL) administration to human vascular smooth muscle cells (HVSMCs), followed by injection with oe-NC, oe-FUS, oe-Sfrp5, or oe-FUS+ oe-Sfrp5. Western blot, Transwell assay, CCK8 assay, Oil Red O staining assay, and ELISA were used to elucidate the mechanisms of the FUS/Sfrp5/Wnt5 pathway in our model of AS.</p><p><strong>Results: </strong>In this study, both FUS and Sfrp5 inhibited Wnt5a expression. In addition, FUS inhibited lipid droplet formation and migration capacity of OX-LDL-induced HVSMCs, and FUS and Sfrp5 may have a synergistic effect in controlling Wnt5a in AS. These results highlight the potential therapeutic value of targeting the FUS and Sfrp5 pathway to control AS progression.</p><p><strong>Conclusion: </strong>The findings suggest that FUS and Sfrp5 may have a synergistic effect in controlling Wnt5a in AS.</p>\",\"PeriodicalId\":8228,\"journal\":{\"name\":\"Annals of clinical and laboratory science\",\"volume\":\"55 2\",\"pages\":\"240-246\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of clinical and laboratory science\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"MEDICAL LABORATORY TECHNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of clinical and laboratory science","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的：动脉粥样硬化（AS）在心血管疾病的发生发展中起着重要作用。尽管最近医学治疗取得了进展，但AS患者的预后仍然令人不满意。这项研究旨在增强我们对AS的理解，并为开发更有效的治疗方法铺平道路，以改善患者的预后，并最终减轻这种毁灭性疾病的负担。方法：将氧化低密度脂蛋白（OX-LDL）注入人血管平滑肌细胞（HVSMCs），建立AS细胞模型，然后注射oe-NC、oe-FUS、oe-Sfrp5或oe-FUS+ oe-Sfrp5。采用Western blot、Transwell法、CCK8法、Oil Red O染色法和ELISA法，对FUS/ strp5 /Wnt5通路在AS模型中的作用机制进行了分析。结果：在本研究中，FUS和strp5均抑制Wnt5a的表达。此外，FUS抑制ox - ldl诱导的HVSMCs的脂滴形成和迁移能力，FUS和strp5可能在控制AS中的Wnt5a中具有协同作用。这些结果强调了靶向FUS和strp5通路控制AS进展的潜在治疗价值。结论：研究结果提示FUS和strp5在控制AS中Wnt5a可能具有协同作用。
Expression and Effects of FUS/Sfrp5/Wnt5 in Atherosclerosis Development.
Objective: Atherosclerosis (AS) contributes significantly to the development of cardiovascular disease. Despite recent advances in medical treatment, the outcomes for patients with AS are still unsatisfactory. This study aims to enhance our understanding of AS and pave the way for the development of more effective therapeutic approaches to improve patient outcomes and ultimately reduce the burden of this devastating condition.
Methods: An AS cell model was established using oxidized low-density lipoprotein (OX-LDL) administration to human vascular smooth muscle cells (HVSMCs), followed by injection with oe-NC, oe-FUS, oe-Sfrp5, or oe-FUS+ oe-Sfrp5. Western blot, Transwell assay, CCK8 assay, Oil Red O staining assay, and ELISA were used to elucidate the mechanisms of the FUS/Sfrp5/Wnt5 pathway in our model of AS.
Results: In this study, both FUS and Sfrp5 inhibited Wnt5a expression. In addition, FUS inhibited lipid droplet formation and migration capacity of OX-LDL-induced HVSMCs, and FUS and Sfrp5 may have a synergistic effect in controlling Wnt5a in AS. These results highlight the potential therapeutic value of targeting the FUS and Sfrp5 pathway to control AS progression.
Conclusion: The findings suggest that FUS and Sfrp5 may have a synergistic effect in controlling Wnt5a in AS.
期刊介绍：
The Annals of Clinical & Laboratory Science
welcomes manuscripts that report research in clinical
science, including pathology, clinical chemistry,
biotechnology, molecular biology, cytogenetics,
microbiology, immunology, hematology, transfusion
medicine, organ and tissue transplantation, therapeutics, toxicology, and clinical informatics.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
